Eloralintide, petrelintide and amycretin: the amylin drugs in trials
Reviewed 32 sourcesPublished by PepVault
Eloralintide, petrelintide and amycretin side by side: the doses their trials used, weight loss vs placebo, side effects and phase 3 status as of Nov 2026.

- Last reviewed
- Sources
- 32
- Questions
- 8
- Compounds
- 5
The short answer
Eloralintide, petrelintide and amycretin are weekly amylin-based shots, all in phase 3 and none approved as of November 20, 2026. Eloralintide's phase 2 trial gave 1 to 9 mg a week, some arms stepping up from 3 or 6 mg, and 9 mg brought 20.1% weight loss at 48 weeks. Petrelintide reached about 10%; amycretin, which adds GLP-1, 24% in a small trial.
- Eloralintide (Lilly): 1 to 9 mg weekly in phase 2, 9.5% to 20.1% weight loss at 48 weeks against 0.4% on placebo.
- Petrelintide (Zealand and Roche): 1.0 to 9.0 mg weekly, about 8% to 10% at 28 weeks, with nausea the one side effect well above placebo.
- Amycretin (Novo Nordisk), one molecule acting on GLP-1, amylin and calcitonin receptors: up to 24.3% at 36 weeks on 60 mg weekly in a 125-person trial.
- As of November 20, 2026 all three are in phase 3 and none is FDA approved; the first phase 3 measurements are estimated to end in 2028.
Evidence: Phase 1 and phase 2 randomized trials in people (The Lancet, The Lancet Diabetes & Endocrinology, Diabetes, Obesity and Metabolism), company releases for results not yet in a journal, and registry records for phase 3; every trial is funded by the drug's maker, and none of these drugs is approved.

Which amylin drugs are in trials?
Amylin is a fullness hormone the pancreas releases with insulin after a meal: it slows the stomach and brings fullness on sooner. Our cagrilintide and CagriSema guide covers amylin itself, pramlintide and cagrilintide. Behind them, as of November 20, 2026, at least five more amylin-based drugs are in phase 3, the large trials before an approval79132124, and none is FDA approved29.
| Drug (maker) | Acts on | How often | Phase on Nov 20, 2026 | Main trial so far | Top dose | Weight change vs placebo | How counted |
|---|---|---|---|---|---|---|---|
| Eloralintide (Eli Lilly) | Amylin receptors, far less the calcitonin receptor5 | Weekly shot | Phase 3 since Dec 15, 20258 | Phase 2, 48 weeks1 | 9 mg | −20.1% vs −0.4%2 | On treatment |
| Petrelintide (Zealand Pharma, Roche) | Amylin receptors (a human amylin copy) | Weekly shot | Phase 3 since Sep 30, 202613 | ZUPREME-1, 28 weeks10 | 9.0 mg | −9.4% vs −1.7% (best: 5.0 mg, −9.8%)10 | On treatment |
| Amycretin, now zenagamtide (Novo Nordisk) | GLP-1, amylin and calcitonin receptors, one molecule17 | Weekly shot or daily tablet | Phase 3 since Feb 24, 202621 | Phase 1b/2a, 36 weeks, one site16 | 60 mg | −24.3% vs −1.1%16 | On treatment31 |
| EloraTZP: eloralintide with tirzepatide (Eli Lilly) | Amylin, GIP and GLP-1 receptors | Weekly, two shots in phase 2 | Phase 3 since Oct 16, 20269 | Phase 2b, type 2 diabetes, 48 weeks6 | 9 mg + 15 mg | −23.3% vs −3.0% (tirzepatide alone −14.8%)6 | On treatment |
| Lenbelintide, AZD6234 (AstraZeneca) | Amylin receptors, selectively23 | Weekly shot | Phase 3 since Aug 19, 202624 | Phase 2 done, results not published25 | Not published | Not published | Not published |
Each row is a separate trial with its own people, length and dose steps, so it is not a ranking. All four published rows count on treatment: the loss estimated had everyone kept taking the drug as planned, which runs higher than counting those who stopped.

What doses did the eloralintide trials use?
Eloralintide's phase 2 trial gave 263 adults with obesity or overweight and no type 2 diabetes a weekly shot for 48 weeks1. Four arms took one dose throughout. Two climbed: 6 mg for 20 weeks, then 9 mg; or 3 mg and 6 mg for 4 weeks each, then 9 mg for 40 weeks3. These are trial doses given under the trial's doctors; no approved dose exists.
| Arm | How the dose ran | Weight change at 48 weeks | Nausea | Fatigue |
|---|---|---|---|---|
| 1 mg | Same dose all 48 weeks | −9.5% | 11% | 0% |
| 3 mg | Same dose all 48 weeks | −12.4% | 13% | 13% |
| 6 mg | Same dose all 48 weeks | −17.6% | 64% | 29% |
| 9 mg | Same dose all 48 weeks | −20.1% | 33% | 43% |
| 6 then 9 mg | 6 mg for 20 weeks, then 9 mg | −19.9% | 54% | 46% |
| 3, 6, then 9 mg | 3 mg and 6 mg for 4 weeks each, then 9 mg | −16.4% | 25% | 21% |
| Placebo | A dummy shot | −0.4% | 14% | 12% |
Weight change is on treatment, from Lilly's results2; side-effect rates are from the paper1. The registry posts −9.4% and −16.5% for the 1 mg and slow-climb arms3. Starting high brought the most nausea: 64% on 6 mg from the first shot. The slowest climb cut it to 25% and still reached 16.4%, and side effects at 1 and 3 mg were close to placebo12.
A 12-week phase 1 trial gave fixed weekly doses of 1.2, 3, 6 and 12 mg with no step-up, and weight fell 2.6% to 11.3%4. The phase 3 record for ENLIGHTEN-1 (1,980 adults, weight at 64 weeks) lists four doses without naming them, as does ENLIGHTEN-2 in type 2 diabetes, so the phase 3 doses are not public as of November 20, 202678.
Lilly also pairs eloralintide with tirzepatide (Zepbound, Mounjaro) as EloraTZP. In 367 adults with type 2 diabetes, given as two shots for 48 weeks, the pairs ran from 3 mg with tirzepatide 5 mg (−13.2%) to 9 mg with 15 mg (−23.3%), against −12.3% for eloralintide alone; phase 3 uses one combined product6.
PepVault's dose log keeps each weekly shot with its date and amount, and its reminders hold the shot day. Log it in PepVault
What doses did the petrelintide trials use?
Petrelintide's phase 1 trial stepped weekly doses up every 2 weeks to 2.4, 4.8 or 9.0 mg over 16 weeks, and weight fell by up to 8.6%11. ZUPREME-1, its phase 2 trial, gave 485 adults without diabetes one of five maintenance doses, 1.0, 2.5, 5.0, 7.0 or 9.0 mg weekly, for 42 weeks including the step-ups10.
At 28 weeks, on treatment, weight changed by −7.9% on 1.0 and 2.5 mg, −9.8% on 5.0 mg, −9.3% on 7.0 mg and −9.4% on 9.0 mg, against −1.7% on placebo, and kept falling to −10.7% by week 4210. Above 5 mg, more drug added nothing. The loss is smaller than eloralintide's; petrelintide's case is how gentle it was on the stomach.
Roche now runs phase 3 with Zealand: ZUPREME-3 (3,900 adults without diabetes), ZUPREME-4 (type 2 diabetes) and ZUPREME-5 (heart disease), about 7,000 people in all, each measuring weight at 64 weeks131415.
What doses did the amycretin trials use?
Amycretin is one Novo Nordisk molecule that switches on the GLP-1 receptor, the amylin receptors and the calcitonin receptor, the signals CagriSema gives as two drugs; its official name is now zenagamtide17. In the injection trial for weight, 125 adults at one US site started at 0.3 mg weekly and climbed to 1.25, 5, 20 or 60 mg16.
| Top weekly dose | Weeks in all | Weight change | Placebo |
|---|---|---|---|
| 1.25 mg | 20 | −9.7% | +2.0% |
| 5 mg | 28 | −16.2% | +2.3% |
| 20 mg | 36 | −22.0% | +1.9% |
| 60 mg | 36 | −24.3% | −1.1% |
In the lower three arms the top dose ran for the last 12 weeks. Novo gives these as the loss had everyone stayed on treatment31. The groups were small and many people left for reasons other than side effects, so these numbers are early16.
In type 2 diabetes, the weekly shot started at 0.2 mg and stepped up every 4 weeks to one of six doses from 0.4 to 40 mg; HbA1c, a three-month blood sugar average, fell 0.9 to 1.7 points at 36 weeks17. The daily tablet started at 1.5 mg and stepped up every 4 weeks to 6, 25 or 50 mg18. Weight fell by up to 14.5% on the shot, whose top dose ran only its last 4 weeks, and 10.1% on the tablet, against 2.6% and 2.5% on placebo19.
Tablet and shot milligrams are not interchangeable: each form was tested at its own doses. Phase 3 began with AMAZE 1 on February 24, 2026 (1,150 adults, four weekly doses not named, 84 weeks) and AMAZE 9, for the tablet, on August 31, 2026 (about 950 adults, five daily doses from 6 to 100 mg, 76 weeks)212232.
How is eloralintide different from cagrilintide and petrelintide?
Amylin works through amylin receptors, which are the calcitonin receptor paired with a helper protein30, so many amylin drugs also switch on the calcitonin receptor alone. Cagrilintide, the guide before this one, does5. Eloralintide was built not to: in cell tests it switched on the human amylin 1 receptor 12 times more strongly than the calcitonin receptor5. Petrelintide is a long-acting copy of human amylin made stable near neutral pH so that it could share one shot with other weight drugs12.
Their half-lives, the time for half a dose to clear, differ: about 14 days for eloralintide5, about 10 days for petrelintide11 and about 88 hours for amycretin, after one small dose20. A long half-life keeps levels nearly flat between weekly shots, and each new dose takes weeks to settle, as eloralintide's curve shows.
Try it
How Eloralintide builds up
An estimate from a half-life of about 14 days, one dose a week for four weeks. The shape of the level, not a measurement.
The receptor numbers come from cells in a dish; no trial in people has tested whether the selectivity is easier on the stomach.
What side effects showed up in the trials?
Stomach effects and tiredness lead, mostly mild to moderate and mostly while doses climb. On eloralintide, fatigue rose to 43% on 9 mg against 12% on placebo1. Its posted results also list bradycardia, a slower heart rate, in 9 of 210 people on eloralintide (3 each on 6 mg, 9 mg and the slow climb), and hair thinning in 15 of 210, 6 of them on 9 mg, with none of either among 53 on placebo3.
Petrelintide's profile is its strongest point: nausea in 20% against 6% on placebo, while vomiting (3% against 6%), diarrhoea (7% against 7%) and constipation (7% against 4%) stayed near placebo10. On amycretin, stomach effects led, mostly mild to moderate and gone by the study's end16. Pairing amylin with tirzepatide added them up: 10.8% to 27.0% stopped EloraTZP for side effects, against 2.9% on tirzepatide alone6.
Commonly reported: feeling full sooner and eating smaller portions, a few queasy days after each step-up, and on eloralintide's higher doses, tiredness.
When to get help These drugs are given only inside trials, so a side effect that worries you goes to the trial's study doctor, who decides whether to pause or lower the dose.
Which other amylin drugs are in trials?
- Lenbelintide (AZD6234), AstraZeneca: a selective amylin receptor agonist; a 2026 review reports a half-life of about 4 days and 3.8% off by day 5 after one 2.7 mg shot in phase 123. Its phase 2 trial (262 adults) finished on December 3, 2025, with no weight results published by November 20, 202625; phase 3 started on August 19, 202624.
- ABBV-295 (formerly GUBamy), AbbVie: acts on amylin and calcitonin receptors; the same review reports up to 9.8% off at 12 weeks in phase 123, and a 360-person, 32-week phase 2 trial started on August 4, 202626.
- MET-233i, Pfizer: built for one shot a month, with a half-life of nearly 3 weeks; the review reports more than 8% beyond placebo in about 5 weeks of phase 12327.
- Petrelintide with enicepatide, Roche: a 486-person phase 2 trial of the amylin drug with Roche's GIP and GLP-1 drug, due to start on November 30, 202628.
Amgen's MariTide often sits on these lists, but it is not an amylin drug; our monthly shots guide covers it.
When could the amylin drugs be approved?
Not before their phase 3 trials report. The registries estimate when each trial's main measurement ends: ENLIGHTEN-2 in January 2028, ENLIGHTEN-1 in March 2028, AMAZE 9 in June 2028, SELENE 1 in August 2028, ZUPREME-3 in December 2028 and AMAZE 1 in June 20298722241321, dates sponsors can move. A filing and an FDA review follow, so as of November 20, 2026 none can be prescribed outside a trial. The one amylin pairing further along is CagriSema: Novo filed it with the FDA in December 2025 and expects a US decision in the fourth quarter of 202632; our CagriSema decision guide follows it.
In one of these trials? PepVault's weight log charts every weigh-in over time, so months on a dose read as one line. Track your weight in PepVault
Sources
- Billings LK et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2025;406(10520):2631-2643. PubMed 41207310
- Eli Lilly and Company. Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight. PR Newswire, November 6, 2025. prnewswire.com
- ClinicalTrials.gov NCT06230523: A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight (Eli Lilly; arms and posted results, read November 20, 2026). clinicaltrials.gov
- Bhattachar SN et al. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes Obes Metab. 2026. PubMed 41559929
- Briere DA et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: from discovery to clinical proof of concept. Mol Metab. 2025. PubMed 41109426
- Eli Lilly and Company. Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes. PR Newswire, September 30, 2026. prnewswire.com
- ClinicalTrials.gov NCT07321886: ENLIGHTEN-1, eloralintide in obesity or overweight without type 2 diabetes (Eli Lilly; read November 20, 2026). clinicaltrials.gov
- ClinicalTrials.gov NCT07282600: ENLIGHTEN-2, eloralintide in obesity or overweight and type 2 diabetes (Eli Lilly; started December 15, 2025; read November 20, 2026). clinicaltrials.gov
- ClinicalTrials.gov NCT07881458: AMPLIFY-2, EloraTZP in obesity or overweight and type 2 diabetes (Eli Lilly; started October 16, 2026; read November 20, 2026). clinicaltrials.gov
- Garvey WT et al. Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2026;14(11):914-926. PubMed 42810355
- Brændholt Olsen M et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of petrelintide for weight management: two randomized, controlled phase 1 trials. Diabetes Obes Metab. 2026. PubMed 42017294
- Fischer Munch H et al. Development of petrelintide: a potent, stable, long-acting human amylin analogue. J Med Chem. 2025. PubMed 41217931
- ClinicalTrials.gov NCT07843498: ZUPREME-3, petrelintide in overweight or obesity (Hoffmann-La Roche with Zealand Pharma; started September 30, 2026; read November 20, 2026). clinicaltrials.gov
- ClinicalTrials.gov NCT07843485: ZUPREME-4, petrelintide in overweight or obesity and type 2 diabetes (Hoffmann-La Roche; read November 20, 2026). clinicaltrials.gov
- ClinicalTrials.gov NCT07843472: ZUPREME-5, petrelintide in overweight or obesity and established cardiovascular disease (Hoffmann-La Roche; read November 20, 2026). clinicaltrials.gov
- Dahl K et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. Lancet. 2025;406(10499):149-162. PubMed 40550231
- Mora P et al. Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a dose-finding, phase 2 trial. Lancet. 2026;408(10555):621-635. PubMed 42532080
- Mora P et al. Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a dose-finding, phase 2 trial. Lancet. 2026;408(10555):607-620. PubMed 42532079
- Novo Nordisk A/S. Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes. Form 6-K filed with the SEC, November 25, 2025. sec.gov
- Oldenburg et al. Renal impairment does not affect pharmacokinetics, safety or tolerability of zenagamtide. Diabetes Obes Metab. 2026. PubMed 42443140
- ClinicalTrials.gov NCT07339423: AMAZE 1, NNC0487-0111 (amycretin) for weight loss (Novo Nordisk; started February 24, 2026; read November 20, 2026). clinicaltrials.gov
- ClinicalTrials.gov NCT07720271: AMAZE 9, once-daily oral zenagamtide in obesity (Novo Nordisk; started August 31, 2026; read November 20, 2026). clinicaltrials.gov
- Alhazmi A, le Roux CW. Amylin analogs: the next major class of weight loss therapy: a review of experimental data and early-phase clinical trials. Diabetes Obes Metab. 2026;28 Suppl 5:42-50. PubMed 42452898
- ClinicalTrials.gov NCT07784725: SELENE 1, AZD6234 (lenbelintide) in obesity or overweight without type 2 diabetes (AstraZeneca; started August 19, 2026; read November 20, 2026). clinicaltrials.gov
- ClinicalTrials.gov NCT06595238: APRICUS, AZD6234 phase 2 in obesity or overweight (AstraZeneca; completed December 3, 2025; read November 20, 2026). clinicaltrials.gov
- ClinicalTrials.gov NCT07752979: ABBV-295 phase 2 in obesity or overweight (AbbVie; started August 4, 2026; read November 20, 2026). clinicaltrials.gov
- ClinicalTrials.gov NCT07022977: A Study of MET233 in Individuals With Obesity or Overweight (Pfizer; read November 20, 2026). clinicaltrials.gov
- ClinicalTrials.gov NCT07589686: ZYNERGY, petrelintide co-administered with RO7795068 (enicepatide) (Hoffmann-La Roche; read November 20, 2026). clinicaltrials.gov
- openFDA Drugs@FDA: searches for eloralintide, petrelintide, amycretin, zenagamtide and lenbelintide return no approved products (November 20, 2026). api.fda.gov
- Bailey CJ, Flatt PR, Conlon JM. Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes. Peptides. 2026;196:171480. PubMed 41747885
- Novo Nordisk A/S. Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity. Form 6-K filed with the SEC, January 24, 2025. sec.gov
- Novo Nordisk A/S. Financial report for the period 1 January to 30 September 2026 (R&D update and anticipated milestones). Form 6-K filed with the SEC, November 4, 2026. sec.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.